Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025

GC Biopharma submits IND to begin Phase 3 clinical trial for Barycela in Thailand

FDA expands Repatha indication to adults at risk of major cardiovascular events from uncontrolled LDL-C

The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva

Yatharth Hospitals names Ashutosh Kumar Jha as Group Chief – Strategy, M&A, and Investor Relations

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery

Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1

Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume

Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr

Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025